文献速递乳腺癌支持与姑息治疗

电子患者报告结局监测联合预警干预改善转移性乳腺癌疲劳:随机临床试验

Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

该多中心随机临床试验纳入德国52家乳腺癌中心的924例转移性乳腺癌患者,评估每周电子PRO问卷联合预警电话干预对疲劳的影响。6个月时干预组疲劳T评分较对照组低5.4分(95%CI -6.6至-4.1,P<.001),超过最小临床重要差异3.3分,躯体功能亦改善且超过其MCID。

要点

  • 每周电子PRO监测联合48小时内预警电话干预可显著降低转移性乳腺癌患者6个月疲劳评分。
  • 疲劳改善幅度(-5.4分)超过MCID 3.3分,躯体功能改善(4.0分)亦超过MCID 3.2分。
  • 生活质量组间差异仅0.8分,未达MCID 2.9分。

核心结论

  • 数字PRO监测联合预警干预与转移性乳腺癌患者疲劳的临床意义改善相关。
  • 干预同时改善躯体功能,但生活质量改善未达临床意义阈值。
  • 结果支持在常规肿瘤诊疗中进一步评估基于预警的PRO监测。

研究设计与样本

  • 多中心随机临床试验,2021年5月至2024年2月在德国52家乳腺癌中心开展,随访12个月。
  • 筛查2008例,随机924例(46.0%),主要分析纳入909例(45.3%),中位年龄50岁(范围19-83岁)。
  • 纳入标准为≥18岁转移性乳腺癌女性、接受系统治疗、预期寿命>3个月、能阅读德语且可使用智能手机。

主要发现

  • 基线平均疲劳T评分干预组57.6(SD 9.5),对照组60.2(SD 9.0),P<.001。
  • 6个月调整后平均疲劳评分干预组54.5(95%CI 53.7-55.4),对照组59.9(95%CI 59.0-60.8),平均差-5.4分(95%CI -6.6至-4.1,P<.001),超过MCID 3.3分。
  • 6个月躯体功能干预组更高,平均差4.0(95%CI 2.6-5.4),超过MCID 3.2分。
  • 6个月生活质量组间差0.8分(95%CI 0.02-1.5),低于MCID 2.9分。

临床怎么用

  • 对接受系统治疗的转移性乳腺癌患者,可考虑每周电子PRO问卷监测疲劳等症状。
  • 预设PRO恶化预警后,由培训护士或医生在48小时内电话联系患者进行干预。
  • 关注疲劳和躯体功能改善,但不应预期短期内生活质量有临床意义的提升。

局限性

  • 基线PRO在随机化后、组别特异性随访开始前评估,组间基线疲劳评分存在差异。
  • 研究仅在德国开展,结果外推需考虑医疗体系与数字健康可及性差异。
  • 主要分析纳入909/924例随机患者,存在少量失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Electronic patient-reported outcome (PRO) monitoring has shown benefits in advanced cancer, but data specific to metastatic breast cancer (mBC) remain limited. Fatigue is a common, clinically important, and functionally impairing symptom in mBC, making it a patient-centered target for electronic PRO monitoring. OBJECTIVE: To determine whether digital PRO monitoring with alert-based responses reduces fatigue in patients with mBC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial was conducted from May 2021 to February 2024, with 12 months of follow-up, at 52 breast cancer centers in Germany and included women aged 18 years or older with mBC who were receiving systemic therapy at any point in the metastatic disease course, had a life expectancy of longer than 3 months, were able to read German, and had smartphone access. Data analysis started in February 2024 and lasted 6 months. INTERVENTIONS: The intervention group completed weekly PRO questionnaires via a smartphone using validated short forms from the European Organization for Research and Treatment of Cancer computerized adaptive testing core item bank. Automated alerts based on predefined PRO deterioration were emailed to trained local nurses or physicians, who contacted patients by telephone within 48 hours. The control group received usual care with quarterly PRO questionnaires and no alerts. MAIN OUTCOMES AND MEASURES: The primary outcome was fatigue at 6 months. Secondary outcomes included fatigue, physical functioning, and quality of life over 12 months. PROs were reported as standardized T scores. RESULTS: Of 2008 patients screened, 924 (46.0%) were randomized, and 909 (45.3%) were included in the primary analysis (median age, 50 years [range, 19-83 years]). Baseline mean (SD) fatigue T scores were 57.6 (9.5) in the intervention group and 60.2 (9.0) in the control group (P < .001), with baseline PROs assessed after randomization but before group-specific follow-up began. At 6 months, adjusted mean fatigue was 54.5 (95% CI, 53.7- 55.4) vs 59.9 (95% CI, 59.0-60.8), yielding a mean difference of -5.4 points (95% CI, -6.6 to -4.1; P < .001), exceeding the minimal clinically important difference (MCID) of 3.3 points. At 6 months, physical functioning was higher in the intervention group (mean difference, 4.0; 95% CI, 2.6-5.4), exceeding its MCID (3.2), whereas the between-group difference in quality of life was 0.8 points (95% CI, 0.02-1.5), which was less than the MCID of 2.9. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that digital PRO monitoring was associated with clinically meaningful reductions in fatigue and improved physical functioning. These findings support further evaluation of alert-based PRO monitoring in routine oncology care. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00024015.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Karsten MM, Gebert P, Pross T, et al. Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42560727. doi:10.1001/jamaoncol.2026.2661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。